MTOR and cancer: Further, a recent report highlighted that the cajanine derivative LJ101019C (1 μM), able to enhance Kv1.3 activity and expression, leads to natural killer (NK) cell proliferation and activation via AKT/mammalian Target Of Rapamycin (mTOR) signaling (Geng et al., 2020), representing thus a promising candidate for NK-based immunotherapy against cancer.